171 related articles for article (PubMed ID: 15389819)
1. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.
Babiker AA; Nilsson B; Ronquist G; Carlsson L; Ekdahl KN
Prostate; 2005 Feb; 62(2):105-14. PubMed ID: 15389819
[TBL] [Abstract][Full Text] [Related]
2. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis.
Babiker AA; Ronquist G; Nilsson UR; Nilsson B
Am J Reprod Immunol; 2002 Mar; 47(3):183-92. PubMed ID: 12069204
[TBL] [Abstract][Full Text] [Related]
3. Prothrombotic effect of prostasomes of metastatic cell and seminal origin.
Babiker AA; Hamad OA; Sanchez J; Ronquist G; Nilsson B; Ekdahl KN
Prostate; 2007 Mar; 67(4):378-88. PubMed ID: 17219380
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin.
Babiker AA; Ronquist G; Nilsson B; Ekdahl KN
Prostate; 2006 May; 66(7):675-86. PubMed ID: 16425202
[TBL] [Abstract][Full Text] [Related]
5. Mapping pro- and antiangiogenic factors on the surface of prostasomes of normal and malignant cell origin.
Babiker AA; Magnusson PU; Ronquist G; Nilsson B; Ekdahl KN
Prostate; 2010 Jun; 70(8):834-47. PubMed ID: 20127731
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line.
Llorente A; de Marco MC; Alonso MA
J Cell Sci; 2004 Oct; 117(Pt 22):5343-51. PubMed ID: 15466889
[TBL] [Abstract][Full Text] [Related]
7. Human prostasomes contain chromosomal DNA.
Ronquist KG; Ronquist G; Carlsson L; Larsson A
Prostate; 2009 May; 69(7):737-43. PubMed ID: 19143024
[TBL] [Abstract][Full Text] [Related]
8. Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma.
Babiker AA; Ekdahl KN; Nilsson B; Ronquist G
Semin Thromb Hemost; 2007 Feb; 33(1):80-6. PubMed ID: 17253194
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma.
Carlsson L; Ronquist G; Eliasson R; Egberg N; Larsson A
Int J Androl; 2006 Apr; 29(2):331-8. PubMed ID: 16533355
[TBL] [Abstract][Full Text] [Related]
10. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
11. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer.
Jarvis GA; Li J; Hakulinen J; Brady KA; Nordling S; Dahiya R; Meri S
Int J Cancer; 1997 Jun; 71(6):1049-55. PubMed ID: 9185710
[TBL] [Abstract][Full Text] [Related]
13. Effect of glycosylphosphatidylinositol specific phospholipase D gene expression levels on complement mediated killing of leukemic cells in patients with chronic myeloid leukemia.
Jian-Hua T; Xiao-Jie Z; Yi-Dan W; Wen-Kai L; Wang-Jiao H; Cheng-Hong W; Gui-Yuan L
Clin Chim Acta; 2005 Sep; 359(1-2):115-24. PubMed ID: 15907827
[TBL] [Abstract][Full Text] [Related]
14. GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells.
Rooney IA; Heuser JE; Atkinson JP
J Clin Invest; 1996 Apr; 97(7):1675-86. PubMed ID: 8601633
[TBL] [Abstract][Full Text] [Related]
15. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
De Nardo C; Fonsatti E; Sigalotti L; Calabrò L; Colizzi F; Cortini E; Coral S; Altomonte M; Maio M
J Cell Physiol; 2002 Feb; 190(2):200-6. PubMed ID: 11807824
[TBL] [Abstract][Full Text] [Related]
16. Prostasomes, angiogenesis, and tissue factor.
Delves GH; Stewart AB; Cooper AJ; Lwaleed BA
Semin Thromb Hemost; 2007 Feb; 33(1):75-9. PubMed ID: 17253193
[TBL] [Abstract][Full Text] [Related]
17. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia.
Barros MM; Yamamoto M; Figueiredo MS; Cançado R; Kimura EY; Langhi DM; Chiattone CS; Bordin JO
Transfusion; 2009 Jan; 49(1):154-60. PubMed ID: 18954403
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer.
Tappel A
Med Hypotheses; 2005; 64(6):1170-2. PubMed ID: 15823710
[TBL] [Abstract][Full Text] [Related]
19. Glycophosphatidylinositol-anchored protein deficiency as a marker of mutator phenotypes in cancer.
Chen R; Eshleman JR; Brodsky RA; Medof ME
Cancer Res; 2001 Jan; 61(2):654-8. PubMed ID: 11212264
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the promoters and 5'-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes.
Qin X; Ferris S; Hu W; Guo F; Ziegeler G; Halperin JA
Genes Immun; 2006 Jun; 7(4):287-97. PubMed ID: 16541098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
